Thus, inhibiting STIM1-dependent Ca2+ signaling by specifically targeting STIM1 activation and translocation in cancer cells is a potential target for cancer therapy for breast [17], cervical[18], colon[19, 20], prostate[21] and hepatic cancer [22]. Here, STIM1 is linked to cancer.